Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Submitted by
admin
on May 3, 2017 - 2:15pm
Source:
Fierce Pharma
News Tags:
Pfizer
Xtandi
Medivation
Headline:
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Do Not Allow Advertisers to Use My Personal information
